StreetAlpha.app
Home › Stocks › AMPH

Amphastar Pharmaceuticals, Inc. (AMPH)

Healthcare
$28.25
▲ +0.50%
LAST CLOSE · NOV 20

Amphastar makes injectable, inhaled and nasal medicines, including generics and proprietary products, sold to patients and healthcare providers. It last closed at $28.25 on Nov 20, up 0.50% on the day. The next earnings report for AMPH is expected around Thu, Feb 25, 2027, after the close. For the quarter ended Sep 2026, AMPH reported EPS of $0.87 on revenue of $207.6M, with revenue up 8.2% from a year ago. Over its last 8 reports the stock moved an average of 9.3% the session after earnings. Over the last 12 months AMPH insiders bought $0 of stock on the open market and sold $2.4M, according to SEC Form 4 filings.

AI Auto Pilots
Is AMPH in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold AMPH.

Key Stats

Last 12 months
Results
Revenue
$745.8M
+3.1% vs a year ago
Net income
$99.0M
−11.3% vs a year ago
EPS (diluted)
$2.18
−3.5% vs a year ago
Free cash flow
$139.0M
18.6% margin
Valuation
Market cap
$1.2B
42.7M shares
P/E
13.0
Price over 12 month EPS
Price to sales
1.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$204.6M
At Sep 30
Shareholder equity
$814.6M
Buybacks
$95.7M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $437.8M$437.8MFY2021FY2022: $499.0M$499.0MFY2022FY2023: $644.4M$644.4MFY2023FY2024: $732.0M$732.0MFY2024FY2025: $719.9M$719.9MFY2025

From AMPH's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Feb 25
Estimated date · After the close
Reported EPS
$0.87
Quarter ended Sep 2026
Year ago EPS
$0.37
+135.1% on a GAAP basis
Revenue
$207.6M
+8.2% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.74Dec '24Mar 2025: $0.51Mar '25Jun 2025: $0.64Jun '25Sep 2025: $0.37Sep '25Dec 2025: $0.51Dec '25Mar 2026: $0.14Mar '26Jun 2026: $0.67Jun '26Sep 2026: $0.87Sep '26Latest $0.87
Revenue by quarter
Dec 2024: $186.5MDec '24Mar 2025: $170.5MMar '25Jun 2025: $174.4MJun '25Sep 2025: $191.8MSep '25Dec 2025: $183.1MDec '25Mar 2026: $171.2MMar '26Jun 2026: $183.9MJun '26Sep 2026: $207.6MSep '26Latest $207.6M
How AMPH moved after its last 8 reports
Average move the session after a report ±9.3%
Nov 5, 2026After the close+3.0%
Aug 6, 2026After the close+4.9%
May 7, 2026After the close−20.9%
Feb 26, 2026After the close−23.6%
Nov 6, 2025After the close−0.8%
Aug 7, 2025After the close+10.1%
May 7, 2025After the close+0.9%
Feb 27, 2025After the close−9.7%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on AMPHStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on AMPH
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on AMPH

Technical Analysis

AMPH · as of the Nov 20 close · updated each morning
Uptrend

The stock is 1% above its 20 day and 6% above its 50 day average. It is 21% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 54). The nearest support is the 20 day average at $28.00, and the nearest resistance the Pivot R1 at $28.70.

Short trendBullish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityHigh, 4.0%/day
Key levels
$31.0052 week high+9.7%
$31.00Swing high (Nov 6)+9.7%
$28.70Pivot R1+1.6%
$28.25Pivot+0.0%
$28.25Last close
$28.0020 day average−0.9%
$27.79Pivot S1−1.6%
$26.5150 day average−6.2%
$25.03Swing low (Oct 6)−11.4%
$23.64100 day average−16.3%
$22.38200 day average−20.8%
$16.6452 week low−41.1%
Indicators
RSI (14)54.21Middle of its rangeNeutral
MACD0.78Below its signal lineBearish
Stochastic45.6Middle of its rangeNeutral
ADX (14)43.7Strong uptrend
Williams %R-66.2Oversold below −80, overbought above −20Neutral
CCI (20)13.5Oversold below −100, overbought above 100Neutral
Rate of change−0.8%Change over 10 sessionsBearish
ATR (14)$1.12Typical daily range, 4.0% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for AMPH

What happened before

See how AMPH did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow AMPH usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How AMPH has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for AMPHHow many large options trades hit AMPH, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

AMPH Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ●110 buying vs 96 selling
  • ▲Held by funds +5.7 pts
  • ▲Funds holding +16
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding227211+7.6%
In funds' top 1020–
Held by funds72.2%66.5%+5.7 pts
New / increased37 / 7331 / 63+17.0%
Reduced / sold out73 / 2375 / 33−11.1%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AMPH institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AMPH Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$2.4M10 sales · 4 insiders
60% of the selling was under pre-arranged trading plans.
2025-12 sold $364K2026-08 sold $346K2026-09 sold $418K2026-11 sold $1.1MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 16William J PetersCfo, EVP & TreasurerSale plan11,000$29.99$330K
Nov 5William J PetersCfo, EVP & TreasurerSale plan28,631$28.45$815K
Sep 21William J PetersCfo, EVP & TreasurerSale plan4,139$25.00$103K
Sep 16Rong ZhouSenior Evp, Production CenterSale10,000$23.94$239K
Sep 2Rong ZhouSenior Evp, Production CenterSale3,187$23.63$75K
Aug 11Richard K PrinsDirectorSale7,973$20.30$162K
Every insider buy and sale for AMPH over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See AMPH insider trades →

From SEC Form 4 filings by AMPH's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AMPH is in one of them and how their past AMPH trades turned out.

AMPH in the AI portfolios
Loading…

AMPH News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AMPH in an article yet. Here's the latest on the wider market.

AMPH in the news

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals is a pharmaceutical company based in Rancho Cucamonga, California. It develops, manufactures and sells injectable, inhalation and nasal drug products, including generic and proprietary medicines, as well as active pharmaceutical ingredients. Its best-known products include BAQSIMI, a nasal glucagon for severe low blood sugar in people with diabetes, and Primatene MIST, an asthma inhaler sold without a prescription. Its customers include patients and healthcare providers in the United States and in international markets.

Headquarters
Rancho Cucamonga, CA